Paraparetic Guillain-Barré syndrome
|
|
- Crystal Day
- 5 years ago
- Views:
Transcription
1 Paraparetic Guillain-Barré syndrome Bianca van den Berg, MD Christiaan Fokke, MD Judith Drenthen, MD Pieter A. van Doorn, MD, PhD Bart C. Jacobs, MD, PhD Correspondence to Dr. Jacobs: ABSTRACT Objective: To define the clinical and diagnostic characteristics of paraparetic Guillain-Barré syndrome (GBS) with weakness restricted to the legs, compared with the classic quadriparetic GBS. Methods: Prospectively collected data from a cohort of 490 patients with GBS, previously involved in therapeutic or clinical studies, were used to define the demography, clinical presentation, diagnostic investigations, and clinical course in patients with paraparesis during a 6-month follow-up. Results: Forty patients (8%) presented with a paraparesis without weakness of arms and hands. In 29 patients (73%), normal strength of upper extremities persisted during the follow-up period. Patients with paraparesis compared to patients with quadriparesis had a milder form of GBS, with less frequent cranial nerve involvement and less severe leg weakness, despite the fact that the majority of these patients were unable to walk unaided. Median time between onset of weakness and study entry was 6 days (interquartile range 4 11 days) for patients with paraparesis compared with 5 days (interquartile range 3 8 days) for patients with quadriparesis (p ). Fifty percent of patients with paraparesis presented with arm sensory deficits and 73% had reduced or absent arm reflexes. Nerve conduction studies demonstrated arm nerve involvement in 89% of these patients. At 6 months of follow-up, 98% of patients with paraparesis were able to walk unaided compared with 81% of the patients with quadriparesis (p ). There was no association between paraparesis and age, sex, or preceding infections. Conclusions: Paraparesis is an atypical clinical presentation or subform of GBS in which the diagnosis is usually supported by the presence of sensory deficits, reduced reflexes, or abnormal nerve conduction of the arms. Neurology 2014;82: GLOSSARY GBS 5 Guillain-Barré syndrome; Ig 5 immunoglobulin; MRC 5 Medical Research Council; NCS 5 nerve conduction study. Guillain-Barré syndrome (GBS) is a medical emergency requiring early diagnosis for accurate monitoring and treatment. 1,2 The diagnosis of GBS is largely based on a set of clinical characteristics, especially the presence of a rapidly progressive flaccid limb weakness and reduced reflexes, usually in combination with cranial or sensory nerve deficits. 3,4 In the majority of cases with classic quadriparesis, the diagnosis is straightforward. However, GBS is a clinically heterogeneous neuropathy and variant forms have been described that differ from the typical presentation Examples are the Miller Fisher syndrome, the pharyngeal-cervical-brachial variant, and the pure motor variant of GBS In patients with a variant or atypical form of GBS, the diagnosis can be difficult and delayed. Early diagnosis is important in these atypical cases, because patients with these variants may progress to full-blown GBS with respiratory failure and autonomic dysfunction. 5,8 Paraparetic forms of GBS have been described before, but only in smaller case series and without comparison with quadriparetic GBS Thereislittleawarenessof theexistenceofthisvariant,whichmaycauseaconsiderabledelayindiagnosis.theaimofthe current study was to identify the frequency of paraparetic GBS and to describe the clinical From the Departments of Neurology (B.v.d.B., C.F., J.D., P.A.v.D., B.C.J.), Immunology (C.F., B.C.J.), and Clinical Neurophysiology (J.D.), Erasmus MC, University Medical Centre Rotterdam; and Department of Neurology (C.F.), Gelre Hospitals Apeldoorn, the Netherlands. Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article American Academy of Neurology
2 presentation and course of these patients in detail. In addition, we aim to provide a strategy for early and accurate diagnosis in these patients. METHODS In this study, we reviewed prospectively collected data from 567 patients with GBS included in 4 studies performed by the Dutch GBS Study Group. These patients with GBS previously participated in 2 randomized controlled trials, 1 pilot study, and 1 observational study All patients fulfill the diagnostic criteria of GBS. 3 In the 2 randomized controlled trials and the pilot study, patients were included if onset of weakness was less than 2 weeks previous to enrollment and if the patient was unable to walk unaided. 15,17,18 In the observational study, patients with a relatively mild form of GBS, who were still able to walk unaided, were also included. 16 All patients had a routine diagnostic workup to exclude other diagnoses and to confirm GBS. The follow-up duration was at least 6 months. 19 Seventy-seven patients (13.6%) were excluded, including children (n 5 32), patients with Miller Fisher syndrome (n 5 18), acute onset chronic inflammatory demyelinating polyneuropathy (n 5 10), Bickerstaff encephalitis (n 5 2), missing data about distribution of weakness at entry (n 5 4), alternative diagnosis appearing during follow-up (myelitis transversa, Sjögren syndrome, spinal disk herniation, uncertain diagnosis, sacral tumor, vasculitis) (n 5 10), and a previous episode of GBS (n 5 1). For the remaining 490 patients included in the current study, data were collected about age, sex, preceding infections, severity and distribution of weakness, sensory disturbances and reflexes in arms and legs, cranial nerve deficits, and pain. The GBS disability score, ranging from 0 (healthy) to 6 (death), was documented, with a score of 3 indicating that a patient is not able to walk 10 m without help. 20 The Medical Research Council (MRC) sum score was used to register weakness and is a sum of 6 bilateral muscles, 3 bilateral muscles in arms and 3 bilateral muscles in legs, resulting in a score ranging from 0 (quadriplegic) to 60 (normal strength). 21 Results of laboratory investigations, including infection serology and immunoglobulin (Ig)M and IgG antibodies to the gangliosides GM1, GD1a, and GQ1b, and CSF studies, nerve physiology, and neuroimaging were also collected. Paraparetic GBS was defined as weakness of both legs in combination with a normal strength in the muscle groups of the upper extremities included in the MRC sum score (shoulder abduction, elbow flexion, wrist extension) at study entry. Normal strength in hand and other arm muscles (not included in the MRC sum score) was confirmed by reviewing the discharge letter and case record forms of the patients. Patients with paraparesis were compared to patients with quadriparesis regarding clinical features, symptoms of preceding infection, and results of additional investigations, disease severity, and outcome. Standard protocol approvals, registrations, and patient consents. The studies were approved by an ethical standards committee on human experimentation, and informed consent was obtained from all patients. Statistics. SPSS statistics 20.0 (IBM Corp., Armonk, NY) was used for data analysis. A 2-sided p value,0.05 was considered to be statistically significant. The x 2 or Fisher exact test was used to compare proportions. Continuous variables were presented as medians and interquartile ranges and compared using the Mann-Whitney U test. Kaplan-Meier analysis was used to compare the clinical course of patients with paraparesis vs quadriparesis. RESULTS Forty patients with GBS (8%) had a paraparesis of the legs with no weakness in the upper extremities. Compared to patients with quadriparesis, this subgroup had a relatively mild form of GBS (table 1). Patients with paraparesis had less severe leg weakness compared to patients with quadriparesis, as indicated by the higher MRC scores of the leg muscle groups in the MRC sum score. In addition, patients with paraparesis had less frequent cranial nerve involvement and respiratory failure compared to patients with quadriparesis. Patients with paraparesis in general also had a milder disability than patients with quadriparesis, as indicated by a larger proportion of patients with a lower GBS disability score, despite the fact that 36 patients (90%) with paraparesis were unable to walk independently at nadir and 1 patient (3%) died. Also, a lower proportion of patients with paraparesis vs patients with quadriparesis received treatment. Time between onset of weakness and study entry was longer in patients with paraparesis than in those with quadriparesis. There were no differences between patients with paraparesis vs quadriparesis in age, sex, type of antecedent infection, findings in CSF, and electrophysiologic subtype (table 1). More details of the specific diagnostic features of patients with paraparesis are provided in table 2. Most patients with paraparesis had a diffuse distribution of leg weakness, but in some patients, only the proximal or distal muscles were affected. Normal strength of the arms persisted during follow-up in 29 (73%) of these patients. Neurologic examination of the arms at entry demonstrated sensory deficits in 50% and reduced or absent reflexes in 73% of patients. A sensory level was not reported in any of the patients with paraparesis; 14% had symptoms of bladder dysfunction. Nerve conduction studies (NCS), performed at a median of 16 days (interquartile range 8 25 days) after onset of weakness, demonstrated abnormalities of arm nerves in 89% of patients with paraparesis. Decreased compound muscle action potential amplitudes in one of the arm nerves was the most common finding, together with abnormalities in needle EMG, followed by a prolonged distal motor latency and abnormalities in F-wave latency. However, 57% (20/35) showed fewer than 3 of these abnormalities in NCS of the arms. The cell count in CSF was 0 5 cells/ml in 79%, 5 10 cells/ml in 5%, and cells/ml in 16% of patients with paraparesis. This distribution in cell count was not significantly different from the distribution in patients with quadriparesis. Data from imaging studies were available from 12 (30%) of the 40 patients with paraparesis, and in none were abnormalities found that could indicate a diagnosis other than GBS. One of the patients with paraparesis had anti-gm1 IgM antibodies, one other patient was Neurology 82 June 3,
3 Table 1 Clinical characteristics of patients with paraparetic vs quadriparetic GBS Patient characteristic Paraparetic (n 5 40) Quadriparetic (n 5 450) p Value Males 63 (25) 55 (248) 0.37 Age, y 51 (38 69) 53 (36 66) 0.90 Neurologic symptoms at entry Cranial nerve involvement 15 (6) 38 (171/449) Sensory deficits upper or lower extremities 75 (27/36) 66 (292/441) 0.28 Pain 52 (229/441) 71 (27/38) MRC score 6 arm muscles a (18 25),0.001 MRC score 6 leg muscles b 24 (22 26) 20 (15 24),0.001 GBS disability score c 1 and 2 13 (5/39) 5 (23/450) (22/39) 21 (94/450), (12/39) 64 (286/450), (0/39) 10 (47/450) Decreased reflexes in arms 73 (24/33) 89 (322/361) 0.01 Decreased reflexes in legs 100 (33/33) 97 (366/376) 1.0 Neurologic symptoms at nadir MRC sum score 54 (48 56) 38 (22 46),0.001 GBS disability score c 1 and 2 8 (3/40) 4 (17/450) (18/40) 14 (62/450), (17/40) 52 (232/450) (1/40) 28 (125/450), (1/40) 3 (14/450) 1.0 Cranial nerve involvement 32 (12/38) 54 (243/448) Additional investigations Elevated CSF protein, >0.58 g/l 73 (29/40) 64 (276/431) 0.28 Nerve conduction studies 0.65 Demyelinating 44 (15/34) 49 (197/403) Axonal 6 (2/34) 6 (25/403) Equivocal 50 (17/34) 40 (162/403) Inexitable 0 (0/34) 4 (15/403) Normal 0 (0/34) 1 (4/403) Clinical course Days from onset of weakness to study entry 6(4 11) 5 (3 8) Duration of progressive phase d 10 (5 13) 8 (5 14) 0.93 Specific treatment, IVIg or PE 88 (35/40) 97 (436/450) Walking unaided at 6 mo 98 (39/40) 81 (360/446) Abbreviations: GBS 5 Guillain-Barré syndrome; IVIg 5 IV immunoglobulin; MRC 5 Medical Research Council; PE 5 plasma exchange. Data are shown as medians (interquartile ranges) or percentages (number of patients). a MRC sum score of 3 bilateral arm muscle groups: upper arm abductors, elbow flexors, and wrist extensors on both sides. b MRC sum score of 3 bilateral leg muscles: hip flexors, knee extensors, and foot dorsal flexors on both sides. c GBS disability score: 0 5 healthy; 1 5 minor symptoms and capable of running; 2 5 able to walk 10 m or more without assistance but unable to run; 3 5 able to walk 10 m across an open space with help; 4 5 bedridden or wheelchair-bound; 5 5 requiring assisted ventilation for at least part of the day; and 6 5 death. d Number of days between onset of weakness and nadir Neurology 82 June 3, 2014
4 Table 2 Clinical features and additional investigations of patients with paraparetic GBS Patient characteristic Paraparetic (n 5 40) Neurologic symptoms at entry Distribution of weakness Hip flexion 4(4 4) Knee extension 4(4 5) Foot dorsiflexion 4(4 5) Reflexes arms Areflexia 39 (13/33) Hyporeflexia 33 (11/33) Normoreflexia 27 (9/33) Sensory deficits arms a 50 (19/38) Bladder dysfunction 14 (2/12) Sensory level 0 (0/28) Neurologic symptoms during follow-up Weakness arms 28 (11/40) Additional investigations Nerve conduction study abnormalities in arms 89 (31/35) Decreased CMAP amplitude 61 (20/33) Prolonged DML 54 (19/35) Prolonged MCV 26 (9/35) Decreased SNAP 46 (13/28) Abnormalities in F-wave latency 53 (10/19) Abnormalities in myogram 61 (11/18) Abbreviations: CMAP 5 compound muscle action potential (mv); DML 5 distal motor latency (ms); GBS 5 Guillain-Barré syndrome; MCV 5 motor conduction velocity (m/s); SNAP 5 sensory nerve action potential (mv). Data are shown as medians (interquartile ranges) or percentages (number of patients). a Sensory deficits arms at neurologic examination. anti-gm1 IgG positive, and one other patient was anti-gd1a IgM positive and anti-gq1b IgM positive. During follow-up, no alternative diagnosis was made despite routine diagnostic workup. Only one patient (3%) in the current cohort had a paraparesis without involvement of the cranial nerves or weakness, sensory deficits, reduced reflexes, or abnormal NCS of the arms. This patient was admitted after 3 weeks of slowly progressive weakness of both legs. Neurologic examination revealed a mild symmetrical weakness of the proximal and distal muscles and areflexia of both legs. CSF showed no cell count and a protein level of 0.80 g/l. MRI of the lumbar spine showed a relative spinal stenosis at L4-5, which could not explain the more extensive weakness in the legs. NCS was compatible with a mild demyelinating neuropathy of the legs. The patient had difficulty walking and was treated with one course of IVIg,afterwhichhefullyrecovered. Patients with paraparesis in general had a better outcome than patients with quadriparesis. After a follow-up of 6 months, 98% of patients with paraparesis were able to walk unaided, compared with 81% of patients with quadriparesis (p ). The clinical course of patients with paraparetic vs quadriparetic GBS is shown in the figure. Five patients with paraparesis did not receive specific treatment, but they all reached the level of independent walking. One patient with paraparesis died unexpectedly at 90 days after onset of weakness at a rehabilitation center, probably of a cardiovascular complication. This patient had no arm weakness or respiratory failure and regained the ability to walk. DISCUSSION In the current study, 8% of patients with GBS presented with a paraparesis in absence of weakness of the arms. These patients had symmetrical weakness and reduced reflexes of the legs, and as such fulfilled the current diagnostic criteria for GBS. 3 In a proportion of patients, the diagnosis of GBS was further supported by the presence at study entry of cranial nerve involvement (15%), sensory deficits of the arms (50%), or areflexia of the arms (39%). During the progressive phase, only 28% of patients with paraparesis developed additional weakness of the arms. All patients with paraparesis showed a typical monophasic clinical course with improvement in the following weeks. The diagnosis of GBS was further supported by the findings in CSF, and all patients with paraparesis had an abnormal NCS. Routine diagnostic workup in these patients revealed no other cause for the paraparesis, even after a follow-up of 6 months. The findings in these patients therefore demonstrate that paraparesis can be a first clinical presentation or persistent subform in a proportion of patients with GBS. Compared with patients with typical quadriparetic GBS, the patients with paraparetic GBS were relatively mildly affected, although the majority of patients with paraparesis were unable to walk independently at nadir. Patients with paraparetic vs quadriparetic GBS had less frequent cranial nerve deficits and respiratory failure and less severe weakness of the legs. In our cohort, 88% of patients with paraparesis were treated with IVIg or plasma exchange, usually because they were unable to walk independently. After treatment, these patients showed a faster and more complete recovery than the patients with quadriparesis. The relatively good outcome of patients with paraparesis is probably influenced by the mild severity, which is one of the determinants for good recovery. 22 Together, these findings indicate that paraparetic GBS is a mild or regional form of GBS in which the motor nerves of Neurology 82 June 3,
5 Figure Time to reach the ability to walk unaided in patients with paraparetic vs quadriparetic GBS Kaplan-Meier analysis was conducted in a total of 440 patients with GBS who had detailed information available on clinical course during a follow-up of 6 months. GBS 5 Guillain-Barré syndrome. the legs are most severely affected, but the disease rarely progresses to respiratory failure and quadriparesis. A similar situation occurs in the Miller Fisher syndrome, which in some patients may progress to full-blown Miller Fisher syndrome GBS overlap syndrome with quadriparesis orrespiratoryfailure. At present, it is unknown which microbial or host factors determine the progression and extent of peripheral nerve damage. Genetic host factors may influence the disease severity, as was indicated by the functional polymorphisms in the mannose binding lectin 2 gene, which influences the level and activity of complement in blood and is related to the extent of weakness. 23 There are several limitations of our study. First, the investigated patient cohort may be biased toward typical quadriparetic cases of GBS to certify the inclusion criteria of the therapeutic studies, resulting in an underestimation of the actual frequency of paraparetic GBS. Second, not all patients with paraparetic GBS had imaging to exclude other disorders, especially in patients from the older trials when MRI was not routinely available in the clinic. However, 98% of the patients with paraparesis had either sensory disturbances of the arms or either hypo- or areflexia of the arms, or abnormalities at NCS of the upper extremity that confirmed the diagnosis of GBS, which made additional imaging unnecessary. Only one patient had a paraparesis without involvement of the upper extremities and a lumbar MRI was performed to exclude other diagnoses. None of these patients received another diagnosis during the follow-up and all showed a monophasic course with good recovery. Early recognition of GBS in clinical practice is crucial for accurate monitoring and treatment in the initial progressive phase of disease. Previous studies indicate that the diagnosis may be delayed in atypical clinical presentations, such as in young children. 24 The clinical relevance of the current study is that GBS should be among the differential diagnoses of patients with rapidly progressive symmetrical paraparesis with reduced reflexes. Rapidly progressive flaccid symmetrical paraparesis of the legs may be caused by a spectrum of other causes, including transverse myelitis, spinal cord compression, leptomeningeal malignancy, lymphoma, and infectious or autoimmune caudal equina neuritis. 2 The atypical presentation and differential diagnosis may have caused a delay in diagnosis as indicated by the longer duration between onset of weakness and study entry in patients with paraparesis compared to those with quadriparesis, although paraparetic GBS may also have had a less rapid initial disease progression. Our study indicates that there are important diagnostic clues in the early phase of paraparetic GBS. First, most patients had additional symptoms in neurologic examination indicating GBS, being cranial nerve involvement or sensory deficits or hypoor areflexia of the arms. In addition, involvement of the nerves in the upper extremities was further substantiated by the findings in the NCS. Examination of CSF is important, more to exclude infectious causes related to pleocytosis than to confirm the high protein level that is frequently absent in GBS, especially when examined early in the onset of GBS. 19 If there is a sensory level at neurologic examination or prominent or persistent urinary bladder dysfunction, this should cast doubt on the diagnosis of GBS, and additional imaging studies may be required to exclude the presence of spinal cord or cauda equina compression. In addition, in 95% of cases of GBS, MRI with gadolinium may show enhancement of the cauda equina nerve roots, and in the acute phase has a sensitivity of 83% for the diagnosis of GBS. 25 In conclusion, paraparesis is an infrequent clinical presentation or subform of GBS, but involvement of cranial and arm nerves should raise the suspicion of the accurate diagnosis. AUTHOR CONTRIBUTIONS B. van den Berg contributed to the conceptualization of the study, performed the analysis and interpretation of the data, and drafting and revising of the manuscript. C. Fokke contributed to the conduct and the analysis of the study, interpretation of the data, and revisions of the manuscript. J. Drenthen contributed to the conduct of the study, interpretation of the data, and revisions of the manuscript. Prof. P.A. van Doorn contributed to organizing the clinical studies that provided the data for the study, interpretation of the data, and revising the manuscript. Dr. B.C. Jacobs developed the study design, contributed to the conceptualization of the study, performed the analysis and interpretation of the data, and drafting and revising of the manuscript Neurology 82 June 3, 2014
6 STUDY FUNDING No targeted funding reported. DISCLOSURE B. van den Berg, C. Fokke, and J. Drenthen report no disclosures relevant to the manuscript. P. van Doorn receives research support from the Prinses Beatrix Spierfonds, the GBS-CIDP Foundation International, Baxter Biopharmaceutics, Grifols, and Sanquin Plasma Products. B. Jacobs receives research support from the Netherlands Organization for Health Research and Development, Erasmus MC, Prinses Beatrix Spierfonds, and GBS-CIDP Foundation International, and travel support from Baxter Biopharmaceutics. Go to Neurology.org for full disclosures. Received December 2, Accepted in final form February 28, REFERENCES 1. Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005;62: van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008;7: Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(suppl):S21 S Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29: Mori M, Kuwabara S, Yuki N. Fisher syndrome: clinical features, immunopathogenesis and management. Expert Rev Neurother 2012;12: Van der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG; GBS-Consensus Group of the Dutch Neuromuscular Research Support Centre. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol 2001;45: Visser LH, Van der Meche FG, Van Doorn PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy): a subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 1995;118: Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2014;85: Winer JB. Guillain-Barré syndrome: clinical variants and their pathogenesis. J Neuroimmunol 2011;231: Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012;366: Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol 2013;12: Ropper AH. Miller Fisher syndrome and other acute variants of Guillain-Barré syndrome. Baillieres Clin Neurol 1994;3: Carpo M, Pedotti R, Allaria S, et al. Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies. J Neurol Sci 1999; 168: Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326: Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Study Group. Ann Neurol 1994;35: Ruts L, Drenthen J, Jacobs BC, van Doorn PA; Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 2010;74: van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326: van Koningsveld R, Schmitz PI, Meche FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363: Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2014;137: Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2: Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14: Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011; 76: Geleijns K, Roos A, Houwing-Duistermaat JJ, et al. Mannosebinding lectin contributes to the severity of Guillain-Barré syndrome. J Immunol 2006;177: Roodbol J, de Wit MC, Walgaard C, de Hoog M, Catsman-Berrevoets CE, Jacobs BC. Recognizing Guillain-Barré syndrome in preschool children. Neurology 2011;76: Gorson KC, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barré syndrome. Neurology 1996;47: Neurology 82 June 3,
Diagnosis of Guillain Barré syndrome in children and validation of the Brighton criteria
J Neurol (2017) 264:856 861 DOI 10.1007/s00415-017-8429-8 ORIGINAL COMMUNICATION Diagnosis of Guillain Barré syndrome in children and validation of the Brighton criteria Joyce Roodbol 1,2 Marie-Claire
More informationSupplementary Online Content
Supplementary Online Content Stevens O, Claeys KG, Poesen K, Veroniek S, Van Damme P. Diagnostic challenges and clinical characteristics of hepatitis E virus associated Guillain- Barré syndrome. JAMA Neurol.
More informationdoi: /brain/awt285 Brain 2014: 137;
doi:10.1093/brain/awt285 Brain 2014: 137; 33 43 33 BRAIN A JOURNAL OF NEUROLOGY Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria Christiaan Fokke, 1,2,3,4 Bianca van den Berg, 1,5
More informationThe Role of Cytomegalovirus, Haemophilus Influenzae and Epstein Barr Virus in Guillain Barre Syndrome
ORIGINAL REPORT The Role of Cytomegalovirus, Haemophilus Influenzae and Epstein Barr Virus in Guillain Barre Syndrome Shahriar Nafissi 1, Zahra Vahabi 1, Maryam Sadeghi Ghahar 2, Ali Akbar Amirzargar 2,
More informationRisk Factors of Respiratory Failure in Children with Guillain-Barré Syndrome
Pediatrics and Neonatology (2012) 53, 295e299 Available online at www.sciencedirect.com journal homepage: http://www.pediatr-neonatol.com ORIGINAL ARTICLE Risk Factors of Respiratory Failure in Children
More informationPrediction of Functional Outcome in Axonal Guillain-Barre Syndrome Eun Jung Sung, MD, Dae Yul Kim, MD, Min Cheol Chang, MD, Eun Jae Ko, MD
Original Article Ann Rehabil Med 2016;40(3):481-488 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2016.40.3.481 Annals of Rehabilitation Medicine Prediction of Functional Outcome in Axonal
More informationMiller Fisher Syndrome A variant of Guillan Barré Syndrome. Sarah I. Sheikh, BM BCh, MRCP
Miller Fisher Syndrome A variant of Guillan Barré Syndrome Sarah I. Sheikh, BM BCh, MRCP History of GBS 1859 Jean Baptiste Octave Landry de Thézillat (1826-1865) published his observation on ascending
More informationCurrent treatment in Guillain-Barré Syndrome and myasthenia gravis
4 rd Congress of the European Academy of Neurology Lisbon, Portugal, June 16-19, 2018 Teaching Course 10 Current treatments in neurology Level 1 Current treatment in Guillain-Barré Syndrome and myasthenia
More informationGuillain-Barré syndrome and related disorders
Guillain-Barré syndrome and related disorders Dr Benjamin Wakerley Department of Neurology Gloucestershire Royal Hospital Disclosures Novartis - educational grant Guillain-Barré syndrome and related disorders
More informationAntibody responses to GalC in severe and complicated childhood Guillain-Barré syndrome
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2018 Antibody responses to GalC in severe and complicated childhood Guillain-Barré
More informationGuillain-Barré Syndrome
Guillain-Barré Syndrome Ouch! www.philippelefevre.com Guillain-Barré Syndrome Acute post-infective polyneuropathy Heterogeneous condition with several variant forms Lipid A Neuronal Ganglioside Pathogenesis
More informationCase Report An Unusual Case of Recurrent Guillain-Barre Syndrome of a Different Subtype Five Years after Initial Diagnosis
Case Reports in Neurological Medicine Volume 2013, Article ID 356157, 4 pages http://dx.doi.org/10.1155/2013/356157 Case Report An Unusual Case of Recurrent Guillain-Barre Syndrome of a Different Subtype
More informationImmunopathology of Guillain- Barré syndrome. L. Magy Service de Neurologie Centre de Référence 'Neuropathies Périphériques Rares' CHU Limoges, France
Immunopathology of Guillain- Barré syndrome L. Magy Service de Neurologie Centre de Référence 'Neuropathies Périphériques Rares' CHU Limoges, France What is Guillain-Barré syndrome? An immune-mediated
More informationCIDP + MMN - how to diagnose and treat. Dr Hadi Manji
CIDP + MMN - how to diagnose and treat Dr Hadi Manji Outline Introduction CIDP Diagnosis Clinical features MRI Nerve conduction tests Lumbar puncture Nerve biopsy Treatment IV Ig Steroids Plasma Exchnage
More informationClinical and electrophysiologic features of childhood Guillain-Barré syndrome in Northeast China
Journal of the Formosan Medical Association (2014) 113, 634e639 Available online at www.sciencedirect.com journal homepage: www.jfma-online.com ORIGINAL ARTICLE Clinical and electrophysiologic features
More informationHyperreflexia in Guillain-Barré syndrome: relation with acute motor axonal neuropathy and anti-gm1 antibody
18 Department of Neurology, Chiba University School of Medicine, Chiba, Japan S Kuwabara K Ogawara M Mori T Hattori Department of Neurology, Dokkyo University School of Medicine, Tochigi, Japan M Koga
More informationMultifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment
Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment 7 MMN RM Van den Berg-Vos, H Franssen, JHJ Wokke, HW Van Es, LH Van den Berg Annals of Neurology 2000;
More informationLE SYNDROME DE GUILLAIN-BARRE
FORMATION UNIVERSITAIRE SPECIFIQUE (FUS) Enseignement interuniversitaire MASTER DE SPECIALISATION EN MEDECINE INTERNE Samedi 19 dećembre 2015 Institute of Neurosciences LE SYNDROME DE GUILLAIN-BARRE Peter
More informationFrom the Department of Neurology, University Hospital Birmingham, Birmingham, UK
Q J Med 2002; 95:717 721 Review QJM Treatment of Guillain-Barré syndrome J.B. WINER From the Department of Neurology, University Hospital Birmingham, Birmingham, UK Introduction Although there are earlier
More informationYing Wang 1*, Pei Shang 1, Meiying Xin 1, Jing Bai 1, Chunkui Zhou 1* and Hong-Liang Zhang 1,2*
Wang et al. BMC Neurology (2017) 17:200 DOI 10.1186/s12883-017-0982-3 RESEARCH ARTICLE Open Access The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term
More informationImmune Mediated Neuropathies
Immune Mediated Neuropathies Hernan Gatuslao, M.D. Assistant Professor Department of Neurology Virginia Commonwealth University School of Medicine AIDP and CIDP Acute inflammatory demyelinating polyneuropathy
More informationInternational Journal of Basic & Applied Physiology
ELECTRODIAGNOSTIC FEATURES IN CLINICALLY SUSPECTED GUILLAIN BARRE SYNDROME Asha Shrivastava*, Rashmi Dave**, Sanjeev Shrivastava ***, Brajesh Sharma **** *Professor, ** JR III, *** Assistant Professor,
More informationComparison of electrophysiological findings in axonal and demyelinating Guillain-Barre syndrome
Iranian Journal of Neurology Original Paper Iran J Neurol 2014; 13(3): 138-143 Comparison of electrophysiological findings in axonal and demyelinating Guillain-Barre syndrome Received: 9 Mar 2014 Accepted:
More informationTreatment of multifocal motor neuropathy with interferon-β1a
Treatment of multifocal motor neuropathy with interferon-β1a 12 MMN RM Van den Berg-Vos, LH Van den Berg, H Franssen, PA Van Doorn, ISJ Martina, JHJ Wokke Adapted from Neurology 2000; 54: 1518-1521. Chapter
More informationMultifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment
Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment 11 MMN RM Van den Berg-Vos, H Franssen, JHJ Wokke, LH Van den Berg
More informationORIGINAL CONTRIBUTION. Continuous Spectrum of Pharyngeal-Cervical-Brachial Variant of Guillain-Barré Syndrome
ORIGINAL CONTRIBUTION Continuous Spectrum of Pharyngeal-Cervical-Brachial Variant of Guillain-Barré Syndrome Takahide Nagashima, MD, PhD; Michiaki Koga, MD, PhD; Masaaki Odaka, MD, PhD; Koichi Hirata,
More informationElectrophysiology in the Guillain-Barré Syndrome: Study of 30 Cases
Journal of Bangladesh College of Physicians and Surgeons Vol. 24, No. 2, May 2006 Electrophysiology in the Guillain-Barré Syndrome: Study of 30 Cases NC KUNDU Summary: Thirty consecutive patients diagnosed
More informationSeminar. Guillain-Barré syndrome
Guillain-Barré syndrome Hugh J Willison, Bart C Jacobs, Pieter A van Doorn Guillain-Barré syndrome is the most common and most severe acute paralytic neuropathy, with about 100 000 people developing the
More informationDiagnosis and Management of Immune-mediated Neuropathies
Continuing Medical Education 39 Diagnosis and Management of Immune-mediated Neuropathies Sung-Tsang Hsieh Abstract- Immune-mediate neuropathies, or inflammatory neuropathies are neuropathies due to the
More informationCritical Illness Polyneuropathy CIP and Critical Illness Myopathy CIM. Andrzej Sladkowski
Critical Illness Polyneuropathy CIP and Critical Illness Myopathy CIM Andrzej Sladkowski Potential causes of weakness in the ICU-1 Muscle disease Critical illness myopathy Inflammatory myopathy Hypokalemic
More informationNeuromuscular Respiratory Failure in Guillain-Barre Syndrome: Evaluation of Clinical and Electrodiagnostic Predictors
Original Article Neuromuscular Respiratory Failure in Guillain-Barre Syndrome: Evaluation of Clinical and Electrodiagnostic Predictors Uma Sundar, Elizabeth Abraham, A Gharat, ME Yeolekar, Trupti Trivedi,
More informationChanges in the severity and subtype of Guillain-Barré syndrome admitted to a specialist Neuromedical ICU over a 25 year period
J Neurol (2017) 264:564 569 DOI 10.1007/s00415-016-8380-0 ORIGINAL COMMUNICATION Changes in the severity and subtype of Guillain-Barré syndrome admitted to a specialist Neuromedical ICU over a 25 year
More informationIntravenous immunoglobulin response treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy
Predicting IVIg response in CIDP 1 http://hdl.handle.net/1765/105969 Intravenous immunoglobulin response in Chapter treatment-naïve 3.3 chronic inflammatory demyelinating polyradiculoneuropathy Intravenous
More informationClinical and Neurophysiological Pattern of Guillain-Barré Syndrome in Diabetic and Non Diabetic Patients
Clinical and Neurophysiological Pattern of Guillain-Barré Syndrome in Diabetic and Non Diabetic Patients Shereen Zakarya Department of Neurology, Mansoura University ABSTRACT Objective: To study the clinical
More informationA Case of Acute Sensory Neuropathy Associated with Contrast Enhancement of the Cauda Equina on Magnetic Resonance Imaging
61 Case Report St. Marianna Med. J. Vol. 33, pp. 61 66, 2005 A Case of Acute Sensory Neuropathy Associated with Contrast Enhancement of the Cauda Equina on Magnetic Resonance Imaging Toshinari Kobayashi
More informationDifferential Diagnosis of Neuropathies and Compression. Dr Ashwin Pinto Consultant Neurologist Wessex Neurological Centre
Differential Diagnosis of Neuropathies and Compression Dr Ashwin Pinto Consultant Neurologist Wessex Neurological Centre Outline of talk Mononeuropathies median and anterior interosseous nerve ulnar nerve
More informationSevere Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
doi: 10.2169/internalmedicine.1723-18 http://internmed.jp CASE REPORT Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
More informationGuillain Barré Syndrome: Profile of 120 Patients with respect to Response to Various Modalities of Treatment
IJPMR ORIGINAL ARTICLE 10.5005/jp-journals-10066-0022 Guillain Barré Syndrome Guillain Barré Syndrome: Profile of 120 Patients with respect to Response to Various Modalities of Treatment 1 Vishal A Chafale,
More informationRisk factors for respiratory failure in Guillain-Barre syndrome in Bangladesh: a prospective study
RESEARCH ARTICLE Risk factors for respiratory failure in Guillain-Barre syndrome in Bangladesh: a prospective study Zhahirul Islam 1, *, Nowshin Papri 1, *, Gulshan Ara 2, Tanveen Ishaque 1,3, Arafat U.
More informationThe clinical spectrum of Malaysian patients with. Chronic inflammatory demyelinating polyneuropathy
Neurology Asia 2004; 9 : 39 45 The clinical spectrum of Malaysian patients with chronic inflammatory demyelinating polyneuropathy Khean Jin GOH, Wai Keong NG, Nee Kong CHEW, Chong Tin TAN Division of Neurology,
More informationElectrodiagnostics for Back & Neck Pain. Steven Andersen, MD Providence Physiatry Clinic
Electrodiagnostics for Back & Neck Pain Steven Andersen, MD Providence Physiatry Clinic Electrodiagnostics Electromyography (EMG) Needle EMG exam (NEE) Nerve conduction studies (NCS) Motor Sensory Late
More informationPeripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases
Peripheral neuropathies, neuromuscular junction disorders, & CNS myelin diseases Peripheral neuropathies according to which part affected Axonal Demyelinating with axonal sparing Many times: mixed features
More informationA descriptive study of patients with Guillain-Barré syndrome: Experience from an Australian tertiary level hospital
A descriptive study of patients with Guillain-Barré syndrome: Experience from an Australian tertiary level hospital Emma Foster 1, Luke Bonavia 1, Ashwin Subramaniam 2-4, Cameron Green 1, Ernest Butler
More informationPatogenesi e terapia della Neuropatia Motoria Multifocale
26 Settembre 2014 Patogenesi e terapia della Neuropatia Motoria Multifocale Francesca Gallia Neurologia 2, Ist. Clin. Humanitas Rozzano, Milano Multifocal Motor Neuropathy Rare disorder characterized by:
More informationElectrodiagnostic Variations in Guillain-Barré Syndrome - Retrospective Analysis of 95 Patients
Original Article GCSMC J Med Sci Vol (VI) No (II) July-December 2017 Electrodiagnostic Variations in Guillain-Barré Syndrome - Retrospective Analysis of 95 Patients Chilvana Patel*, Surya Murthy Vishnubhakat**
More informationInfection-Associated Neurological Syndromes
Infection-Associated Neurological Syndromes Anand P, MD PhD Medical Director, BloodCenter of Wisconsin Assistant Professor, Medical College of Wisconsin ASFA Annual Meeting San Antonio, TX, May 8th, 2015
More informationDysphagia as initial manifestation of Guillan-Barrè Syndrome in a child Elda Pitrolo, Simona Santucci, Chiara Cuzzupè, Filippo De Luca
Clinical Case Seminar A7(1-5 ) Dysphagia as initial manifestation of Guillan-Barrè Syndrome in a child Elda Pitrolo, Simona Santucci, Chiara Cuzzupè, Filippo De Luca Department of Human Pathology of Adulthood
More informationAhmed Abbas, Mark Cook, Liong Hiew Fu, Alistair Lewthwaite, Colin Shirley, Yusuf A. Rajabally
2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Accepted Manuscript A case of POEMS mimicking
More informationAssociation of Campylobacter jejuni infection and Guillain- Barré syndrome: a cohort study in the northwest of Iran
The Turkish Journal of Pediatrics 2008; 50: 443-448 Original Association of Campylobacter jejuni infection and Guillain- Barré syndrome: a cohort study in the northwest of Iran Mohammad Barzegar 1, Asghar
More informationNerve Conduction Studies and EMG
Nerve Conduction Studies and EMG Limitations of other methods of investigations of the neuromuscular system - Dr Rob Henderson, Neurologist Assessment of Weakness Thanks Peter Silburn PERIPHERAL NEUROPATHY
More informationS everal antibodies against gangliosides have been detected
568 PAPER Central motor conduction in patients with anti-ganglioside antibody associated neuropathy syndromes and hyperreflexia Y Oshima, T Mitsui, H Yoshino, I Endo, M Kunishige, A Asano, T Matsumoto...
More informationGUILLAIN-BARRE SYNDROME
GUILLAIN-BARRE SYNDROME tarek.sharshar@rpc.aphp.fr University of Versailles Saint-Quentin en Yvelines Raymond Poincaré Teaching Hospital Garches - France STATEMENTS 1. Guillain-Barré Syndrome (GBS) is
More information3/3/2016. International Standards for the Neurologic Classification of Spinal Cord Injury (ISNCSCI)
International Standards for the Neurologic Classification of Spinal Cord Injury (ISNCSCI) American Spinal Injury Association International Spinal Cord Society Presented by Adam Stein, MD Chairman and Professor
More informationGeneral introduction 1. General introduction. Chapter 1. General introduction
General introduction 1 http://hdl.handle.net/1765/105969 General introduction Chapter 1 General introduction 2 Erasmus Medical Center Rotterdam General introduction 3 Immune-mediated polyneuropathies cover
More informationGBS CIDP AND SPECTRUM AND IVIG TREATMENT. Krista Kuitwaard. Spectrum and IVIg treatment. Krista Kuitwaard
GBS and CIDP Spectrum and IVIg treatment AND CIDP Krista Kuitwaard SPECTRUM AND IVIG TREATMENT Krista Kuitwaard GBS and CIDP Spectrum and IVIg treatment Krista Kuitwaard GBS and CIDP Spectrum and IVIg
More informationDetection of Autoantibodies against Gangliosides in Guillain-Barré Syndrome
ISSN 1735-1383 Iran. J. Immunol. September 2010, 7 (3), 198-201 Hong-Liang Zhang, Su-Jie Gao, Yi Yang, Jiang Wu Detection of Autoantibodies against Gangliosides in Guillain-Barré Syndrome Article Type:
More informationCASE REPORT. Abstract. Introduction. Case Report. Tetsuya Miyagi, Katsuyuki Higa, Miwako Kido, Satoshi Ishihara, Ryo Nakachi and Syugo Suwazono
CASE REPORT The Sequential Ultrasonographic, Electrophysiological and MRI Findings in a Patient with the Pharyngeal-cervicalbrachial Variant of Guillain-Barré Syndrome from the Acute Phase to the Chronic
More informationMotor and sensory nerve conduction studies
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Hands-on Course 2 Assessment of peripheral nerves function and structure in suspected peripheral neuropathies
More informationOutcome and its predictors in GuillaineBarré syndrome
1 Neuromuscular Clinic, Department of Neurology, University Hospitals of Leicester, Leicester, UK 2 Department of Neuroscience and Imaging, University G. d Annuzio, Chieti-Pescara, Italy Correspondence
More informationEvaluation of Peripheral Neuropathy. Evaluation of Peripheral Neuropathy - Introduction
Evaluation of Peripheral Neuropathy Chris Edwards, MD Ochsner Neurology, Main Campus Evaluation of Peripheral Neuropathy - Introduction A very common complaint in the clinic Presentation is variable Multiple
More informationUpdate: Plasmapheresis in Neurologic Disorders
Update: Plasmapheresis in Neurologic Disorders Case Presentation A 62-year-old, right-hand-dominant male presented to the emergency department with a 3-day history of progressive weakness. Initially he
More informationA comparison of two patients with Guillain-Barre Syndrome J O H N C O R S I N O, S P T
A comparison of two patients with Guillain-Barre Syndrome J O H N C O R S I N O, S P T Guillain-Barre Acute inflammatory demyelinating polyneuropathy Highly diverse presentation, course, outcome Miller-Fisher:
More informationZKV and Guillain-Barré Syndrome. Silvia N. Tenembaum Pediatric Neurologist
ZKV and Guillain-Barré Syndrome Silvia N. Tenembaum Pediatric Neurologist ZIKA VIRUS- BACKGROUND INFORMATION Arbovirus (Arthropod-borne virus) 1- Flaviviridae family: Dengue (DENV) West Nile (WNV) Yellow
More informationPeripheral Neuropathies
Peripheral Neuropathies ELBA Y. GERENA MALDONADO, MD ACTING ASSISTANT PROFESSOR UNIVERSITY OF WASHINGTON MEDICAL CENTER Objectives Definition Neurophysiology Evaluation of polyneuropathies Cases Summary
More informationGuillain Barre Syndrome: A clinical observational study in Indian paediatric patients
Guillain Barre Syndrome: A clinical observational study in Indian paediatric patients *Shikha Swaroop 1, Bakul B Javadekar 2 Sri Lanka Journal of Child Health, 2017; 46(3): 238-242 Abstract Background:
More informationCOPYRIGHT 2012 THE TRANSVERSE MYELITIS ASSOCIATION. ALL RIGHTS RESERVED
The Transverse Myelitis Association...advocating for those with acute disseminated encephalomyelitis, neuromyelitis optica, optic neuritis and transverse myelitis ACUTE DISSEMINATED ENCEPHALOMYELITIS (ADEM)
More informationGuide to the use of nerve conduction studies (NCS) & electromyography (EMG) for non-neurologists
Guide to the use of nerve conduction studies (NCS) & electromyography (EMG) for non-neurologists What is NCS/EMG? NCS examines the conduction properties of sensory and motor peripheral nerves. For both
More informationAntiphospholipid Antibody in Serum of Guillain-Barre Syndrome Patients
Iraqi JMS Published by Al-Nahrain College of Medicine ISSN 181-79 Email: Iraqi_jms_alnahrain@yahoo.com http://www. colmed-nahrain.edu.iq/ Antiphospholipid Antibody in Serum of Guillain-Barre Syndrome Patients
More informationClinical insights for early detection of acute transverse myelitis in the emergency department
Clin Exp Emerg Med 2015;2(1):44-50 http://dx.doi.org/10.15441/ceem.14.034 Clinical insights for early detection of acute transverse myelitis in the emergency department Yo Huh, Eun-Jung Park, Ju-Won Jung,
More informationGuillain-Barré Syndrome Beth A. Rosen. DOI: /pir
Guillain-Barré Syndrome Beth A. Rosen Pediatrics in Review 2012;33;164 DOI: 10.1542/pir.33-4-164 The online version of this article, along with updated information and services, is located on the World
More informationOriginal Paper. Iran J Neurol 2014; 13(1): 7-12
Iranian Journal of Neurology Original Paper Iran J Neurol 2014; 13(1): 7-12 Correlations between cytomegalovirus, Epstein-Barr virus, anti-ganglioside antibodies, electrodiagnostic findings and functional
More informationCorrelative study between C-reactive protein, clinical severity, and nerve conduction studies in Guillain-Barrè syndrome
Altaweel et al. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (2018) 54:4 https://doi.org/10.1186/s41983-018-0006-2 The Egyptian Journal of Neurology, Psychiatry and Neurosurgery RESEARCH
More informationrole of antiganglioside antibodies
J Neurol Neurosurg Psychiatry 2000;68:191 195 191 Department of Neurology, Chiba University School of Medicine, 1 8 1 Inohana, Chuo-ku, Chiba 260 8670, Japan S Kuwabara K Ogawara K Mizobuchi M Mori T Hattori
More informationRecurrent miller fisher: a new case report and a literature review
e208 F. Barbato et al. Review Clin Ter 2017; 168 (3):e208-213. doi: 10.7417/T.2017.2008 Recurrent miller fisher: a new case report and a literature review F. Barbato 1, A. Di Paolantonio 1, M. Distefano
More information5.1 Alex.
5.1 Alex http://tinyurl.com/neuromakessense Alex is a 20-year-old full-time national serviceman. His only past medical history is asthma, presents to A&E with a 4-day history of bilateral finger weakness
More informationFunctional recovery of untreated human immunodeficiency virus-associated Guillain-Barré syndrome: A case report
Thomas Jefferson University Jefferson Digital Commons Department of Rehabilitation Medicine Faculty Papers Department of Rehabilitation Medicine 11-2011 Functional recovery of untreated human immunodeficiency
More informationThis is a repository copy of Anti-MAG negative distal acquired demyelinating symmetric neuropathy in association with a neuroendocrine tumor..
This is a repository copy of Anti-MAG negative distal acquired demyelinating symmetric neuropathy in association with a neuroendocrine tumor.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk//
More informationThree cases of acute distal demyelinating neuropathy with recovery
https://helda.helsinki.fi Three cases of acute distal demyelinating neuropathy with recovery Österlund-Tauriala, Emilia 2017 Österlund-Tauriala, E & Partanen, J V 2017, ' Three cases of acute distal demyelinating
More informationDistal chronic spinal muscular atrophy involving the hands
Journal ofneurology, Neurosurgery, and Psychiatry, 1978, 41, 653-658 Distal chronic spinal muscular atrophy involving the hands D. J. O'SULLIVAN AND J. G. McLEOD From St Vincent's Hospital, and Department
More informationA Practical Approach to Polyneuropathy SLOCUM DICKSON ANNUAL TEACHING DAY NOVEMBER 4, 2017
A Practical Approach to Polyneuropathy SLOCUM DICKSON ANNUAL TEACHING DAY NOVEMBER 4, 2017 Disclosures Research support from Cytokinetics, Inc Catalyst, Inc Editorial fees from UptoDate. Objectives Describe
More informationComparison of diabetes patients with demyelinating diabetic sensorimotor polyneuropathy to those diagnosed with CIDP
Comparison of diabetes patients with demyelinating diabetic sensorimotor polyneuropathy to those diagnosed with CIDP Samantha K. Dunnigan 1, Hamid Ebadi 1, Ari Breiner 1, Hans D. Katzberg 1, Leif E. Lovblom
More informationMaking sense of Nerve conduction & EMG
Making sense of Nerve conduction & EMG Drs R Arunachalam Consultant Clinical Neurophysiologist Wessex Neurological Centre Southampton University Hospital EMG/NCS EMG machine For the assessment of patients
More informationGuillain - Barre Syndrome - is an acute frequently severe and
12 JAPI march 2013 VOL. 61 Original Article Clinical Profile of Guillain Barre Syndrome Shubhangi Vithal Dhadke 1, Vithal Narayan Dhadke 2, Sachin S Bangar 1, Milind B Korade 3 Abstract Objectives: To
More informationGuillain-Barré syndrome and related disorders
Guillain-Barré syndrome and related disorders Artículo Amato AA RESUMEN En 1859, Landry describió una neuropatía caracterizada por parálisis severa ascendente. Posteriormente, Guillain, Barré y Strohl
More informationJonathan Katz, MD CPMC
Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC Jonathan Katz, MD CPMC First, a bit of background Classic CIDP--TREATABLE MADSAM/Asymmetric Neuropathy Chronic Length Dependent Neuropathy-
More informationTHE ROLE OF THE ANTI GQ1B ANTIBODY IN DIFFERENTIAL. DIGNOSIS OF ACUTE OPTHALMOPARESIS
THE ROLE OF THE ANTI GQ1B ANTIBODY IN DIFFERENTIAL. DIGNOSIS OF ACUTE OPTHALMOPARESIS Abstract Miller Fisher syndrome has a triad of total external ophthalmoplegia, ataxia and areflexia, Botulism is caused
More informationCervical radiculopathy: diagnostic aspects and non-surgical treatment Kuijper, B.
UvA-DARE (Digital Academic Repository) Cervical radiculopathy: diagnostic aspects and non-surgical treatment Kuijper, B. Link to publication Citation for published version (APA): Kuijper, B. (2011). Cervical
More informationSeema Sikka, MD January 18, 2014 TRANSVERSE MYELITIS: A CLINICAL OVERVIEW
Seema Sikka, MD January 18, 2014 TRANSVERSE MYELITIS: A CLINICAL OVERVIEW DISCLOSURES I have no industry relationships to disclose. I will not discuss off-label use. OBJECTIVES: TRANSVERSE MYELITIS Review
More informationHow to Think like a Neurologist Review of Exam Process and Assessment Findings
Lehigh Valley Health Network LVHN Scholarly Works Neurology Update for the Non-Neurologist 2013 Neurology Update for the Non-Neurologist Feb 20th, 5:10 PM - 5:40 PM How to Think like a Neurologist Review
More informationDiagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline
J Neurol Neurosurg Psychiatry 2001;71:205 209 205 Department of Neurology, Academic Medical Centre, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands N R Rosenberg P Portegies M
More informationThe Internist s Approach to Neuropathy
The Internist s Approach to Neuropathy VOLKAN GRANIT, MD, MSC ASSISTANT PROFESSOR OF NEUROLOGY NEUROMUSCU LAR DIVISION UNIVERSITY OF MIAMI, MILLER SCHOOL OF MEDICINE RELEVANT DECLARATIONS Financial disclosures:
More informationSEMESTER Suriname study. The Suriname Meningo- encephalitis Study (SMS) Introduction. SMS- protocol version 3.4. Principal investigators:
SEMESTER Suriname study The Suriname Meningo- encephalitis Study (SMS) Principal investigators: E.C.M. van Gorp 1,2 and S. Vreden 3 Participating investigators: H. Alberga 4, M. Baptista 5, R. Cruden 4,
More informationTable 1: Nerve Conduction Studies (summarised)
Table 1: Nerve Conduction Studies (summarised) Sensory nerve conduction 1 week* 3 months Superficial radial sensory Normal, symmetric SNAP and CV No change Median to digit II Normal, symmetric SNAP and
More informationA/Professor Arun Aggarwal Balmain Hospital
A/Professor Arun Aggarwal Balmain Hospital Nerve Conduction Studies Test to evaluate the function of motor / sensory nerves Evaluate Paraesthesia (numbness, tingling, burning) Weakness of arms and legs
More informationMyelitis. Case 2. History. Examination. Mahtab Ghadiri
Case 2 Myelitis Mahtab Ghadiri History A 42-year-old man presented to the emergency department with altered sensation in the lower limbs and difficulty ambulating. He first noted paresthesia in his feet
More informationGuillain-Barré Syndrome Mazen M. Dimachkie, M.D 1,* Richard J. Barohn, M.D 2
Current Treatment Options in Neurology (2013) 15:338 349 DOI 10.1007/s11940-013-0231-z NEUROIMMUNOLOGY (RP LISAK, SECTION EDITOR) Guillain-Barré Syndrome Mazen M. Dimachkie, M.D 1,* Richard J. Barohn,
More informationA Tale of Five Demyelinating Neuropathies
Objectives A Tale of Five Demyelinating Neuropathies Tahseen Mozaffar, MD FAAN Professor and Vice Chair of Neurology Director, UC Irvine-MDA ALS and Neuromuscular Center Director, Neurology Residency Training
More informationNeurophysiological Diagnosis of Birth Brachial Plexus Palsy. Dr Grace Ng Department of Paed PMH
Neurophysiological Diagnosis of Birth Brachial Plexus Palsy Dr Grace Ng Department of Paed PMH Brachial Plexus Anatomy Brachial Plexus Cords Medial cord: motor and sensory conduction for median and ulnar
More informationWorld Journal of Pharmaceutical Research
World Journal of Pharmaceutical research Al-Aubaidy et al. Volume 3, Issue 2, XXX-XXX. Research Article ISSN 2277 7105 RESPONSE OF ANTI-CARDIOLIPIN ANTIBODIES TO VARIOUS TREATMENT MODALITIES IN GUILLAIN
More informationAcute bilateral vision deficit as the initial symptom in Guillain Barre syndrome: A case report
EXPERIMENTAL AND THERAPEUTIC MEDICINE Acute bilateral vision deficit as the initial symptom in Guillain Barre syndrome: A case report HUI JUN WEN Department of Neurology, Baoji Municipal Central Hospital,
More information